EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Efficacy and Safety of Syk and BTK Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Emerging Evidence

Amirhossein Heidari iD, Amirhossein Shahbazi Mazid iD, Mohammad Behroozfar iD, Negar Ghotbi iD, Fatemeh Fathabadi iD, Sara Eghbali iD, Nazila Heidari iD

Mediators of Inflammation · 2025-01 · 2025 (1)

DOI: 10.1155/mi/5578929 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Mediators of Inflammation, online erschienen am 10.05.2025. Verfasst von Amirhossein Heidari und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. Hauptthemen laut MEDLINE: Syk Kinase, Agammaglobulinaemia Tyrosine Kinase, Protein Kinase Inhibitors, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a reduced platelet count, resulting in bleeding risks and compromised quality of life. Advances in understanding ITP pathogenesis have revealed critical roles for spleen tyrosine kinase (Syk) and Bruton’s tyrosine kinase (BTK) in Fc receptor (FcR)‐mediated immune pathways, which are central to autoantibody production and platelet destruction. We sought to evaluate the efficacy and safety of Syk and BTK inhibitors in the management of ITP. PubMed/Medline, Scopus, and Web of Science databases were systematically searched up to July 28, 2024. Clinical studies with available full‐text in English were included. Fostamatinib, an FDA‐approved Syk inhibitor, has shown efficacy in enhancing platelet counts and reducing bleeding events in refractory ITP patients. Among the newer Syk inhibitors, sovleplenib demonstrated rapid and sustained platelet increases in clinical trials, with an 80% response rate at the 300 mg dosage and a favorable safety profile. Additionally, BTK inhibitors, including rilzabrutinib and orelabrutinib, have shown potential in clinical trials, offering increased platelet stability and favorable safety profiles in ITP cases. Syk and BTK inhibitors hold potential as targeted therapies for refractory ITP, with evidence supporting their ability to improve clinical outcomes and enhance patient quality of life. Continued research is warranted to optimize these therapies and confirm their long‐term efficacy and safety in diverse patient populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Syk KinaseAgammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsPurpura, Thrombocytopenic, IdiopathicHumansPyrimidinesOxazinesAminopyridinesMorpholines

Stichwörter der Autor:innen

Bruton's tyrosine kinaseITPimmune thrombocytopeniaspleen tyrosine kinase

Substanzen

Syk KinaseAgammaglobulinaemia Tyrosine KinaseProtein Kinase InhibitorsfostamatinibBTK protein, humanSYK protein, humanPyrimidinesOxazinesAminopyridinesMorpholines

Autor:innen und Institutionen

  • Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
  • Cardiovascular Diseases Research Institute, Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen 4032, Hungary.
  • School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
  • School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Amirhossein Heidari, Amirhossein Shahbazi Mazid, Mohammad Behroozfar, Negar Ghotbi, Fatemeh Fathabadi, Sara Eghbali, Nazila Heidari

Zitieren

APA

Heidari, A., Mazid, A. S., Behroozfar, M., Ghotbi, N., Fathabadi, F., Eghbali, S., & Heidari, N. (2025). Efficacy and Safety of Syk and BTK Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Emerging Evidence. Mediators of Inflammation, 2025(1). https://doi.org/10.1155/mi/5578929

Vancouver

Heidari A, Mazid AS, Behroozfar M, Ghotbi N, Fathabadi F, Eghbali S, et al. Efficacy and Safety of Syk and BTK Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Emerging Evidence. Mediators of Inflammation. 2025;2025(1). doi:10.1155/mi/5578929

BibTeX
@article{Heidari2025,
  author = {Heidari, Amirhossein and Mazid, Amirhossein Shahbazi and Behroozfar, Mohammad and Ghotbi, Negar and Fathabadi, Fatemeh and Eghbali, Sara and Heidari, Nazila},
  title = {Efficacy and Safety of Syk and BTK Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Emerging Evidence},
  journal = {Mediators of Inflammation},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/mi/5578929}
}
Kostenlos starten →